Cathie Wood's Ark Invest Scoops Up Iridium, Beam, Pacific Biosciences While Offloading Illumina And Amgen

On Friday, March 21, 2025, the Cathie Wood-led Ark Invest made some notable trades, including significant buys and sells.

Ark Invest's fund bought Iridium Communications Inc. IRDM, Beam Therapeutics Inc. BEAM, Pacific Biosciences of California Inc. PACB and Absci Corp ABSI, while selling Illumina Inc. ILMN, Repare Therapeutics Inc. RPTX, Amgen Inc. AMGN, and Veeva Systems Inc. VEEV.

The IRDM Trade: Ark Invest’s ARK Innovation ETF ARKK, ARK Autonomous Technology & Robotics ETF ARKQ, and ARK Space Exploration & Innovation ETF ARKX funds purchased a total of 68,355 shares of Iridium Communications Inc.

The total value of the shares bought, based on the last close price of $27.65, is approximately $1.89 million.

The BEAM Trade: Ark Invest’s ARKK and Ark Genomic Revolution ETF ARKG funds bought a total of 28,717 shares of Beam Therapeutics Inc.

The total value of the shares bought, based on the last close price of $23.3, is approximately $669,106.

The PACB Trade: Ark Invest’s ARKK fund bought a whopping 243,300 shares of Pacific Biosciences of California Inc.

The total value of the shares bought, based on the last close price of $1.3, is approximately $316,290.

Other Key Trades:

  • Illumina Inc: Ark Invest sold a total of 42,616 shares through ARKK and ARKG.
  • Absci Corp: Ark Invest’s bought 71,392 shares through ARKG.
  • Repare Therapeutics: Ark Invest sold 54,786 shares through ARKG.
  • Amgen Inc: Ark Invest sold 990 shares through ARKG.
  • Veeva Systems Inc: Ark Invest sold 1,322 shares through ARKG.

Read Next:

Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Photo courtesy: Shutterstock

Got Questions? Ask
Which telecommunication stocks could follow Iridium's lead?
How might biotech firms respond to Beam's growth?
What influence will Pacific Biosciences have on genomics?
Which healthcare ETFs could benefit from Ark's trades?
How will Illumina's sell-off affect its market position?
Could Absci Corp see increased interest after Ark's purchase?
What are the implications of Amgen's declining interest for investors?
Which genomic technology companies might gain from this shift?
How could Ark Invest's decisions impact emerging tech?
What other investment opportunities might arise in the biotech sector?
Market News and Data brought to you by Benzinga APIs

Posted In:
Comments
Loading...